Jeffrey M. Ashburner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey M. Ashburner has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Steven J. Atlas
Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
12 shared publications- Steven A. Lubitz
Cardiovascular Research Center, Massachusetts General Hospital, Boston, USA
11 shared publications Daniel E. Singer
Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
10 shared publications- Daniel E. Singer
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA
10 shared publications Yuchiao Chang
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
10 shared publications- Patrick Thomas Ellinor
Massachusetts General Hospital
9 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in Heart Rhythm O2
Real-world performance and diagnostic yield gains of a next-generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor
- 9 October 2026
- Published by Elsevier in Heart Rhythm O2
Open AccessReal-world performance and diagnostic yield gains of a next-generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (7) , e011482
Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial
BACKGROUND: One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches. METHODS: The VITAL-AF trial was a cluster-randomized trial of 1-time, 30-second single-lead ECG screening during primary care visits. It enrolled adults aged ≥65 years in 16 Massachusetts General Hospital primary care practices (2018–2019). In this secondary analysis, we tested 2 approaches to identify subgroups where screening is effective. First, we developed an effect-based model using T-learner, a causal inference approach that estimates screening effects by separately training 2 predictive models—one for screening and one for usual care—and then compares their predictions for each individual. Second, we used a validated AF risk model (Cohorts for Heart and Aging Research in Genomic Epidemiology AF) to test for heterogeneous screening effectiveness. We assessed AF screening effectiveness by quartile of predicted effect and predicted AF risk and determined their correlation. RESULTS: The study included 29 656 participants (mean±SD age 74±7 years, 59% women). In the highest quartile of predicted screening effect, AF diagnosis rates were higher in the screening versus the usual care group (4.00 versus 2.88 per 100 person-years, rate difference 1.12 [95% CI, 0.11–2.13] per 100 person-years). In the highest quartile of predicted AF risk, AF diagnosis rates were also higher in the screening versus the usual care group (5.55 versus 4.23 per 100 person-years, rate difference 1.32 [95% CI, 0.14–2.50] per 100 person-years). Predicted screening effect and predicted AF risk were weakly correlated (Spearman correlation coefficient, 0.23). CONCLUSIONS: One-time screening was associated with increased AF diagnoses in the top quartile of both predicted screening effect and predicted AF risk. Because predicted effect and risk were only weakly correlated, future AF screening efforts should include both high-effect and high-risk individuals.
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (7) , e011482
Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial
BACKGROUND: One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches. METHODS: The VITAL-AF trial was a cluster-randomized trial of 1-time, 30-second single-lead ECG screening during primary care visits. It enrolled adults aged ≥65 years in 16 Massachusetts General Hospital primary care practices (2018–2019). In this secondary analysis, we tested 2 approaches to identify subgroups where screening is effective. First, we developed an effect-based model using T-learner, a causal inference approach that estimates screening effects by separately training 2 predictive models—one for screening and one for usual care—and then compares their predictions for each individual. Second, we used a validated AF risk model (Cohorts for Heart and Aging Research in Genomic Epidemiology AF) to test for heterogeneous screening effectiveness. We assessed AF screening effectiveness by quartile of predicted effect and predicted AF risk and determined their correlation. RESULTS: The study included 29 656 participants (mean±SD age 74±7 years, 59% women). In the highest quartile of predicted screening effect, AF diagnosis rates were higher in the screening versus the usual care group (4.00 versus 2.88 per 100 person-years, rate difference 1.12 [95% CI, 0.11–2.13] per 100 person-years). In the highest quartile of predicted AF risk, AF diagnosis rates were also higher in the screening versus the usual care group (5.55 versus 4.23 per 100 person-years, rate difference 1.32 [95% CI, 0.14–2.50] per 100 person-years). Predicted screening effect and predicted AF risk were weakly correlated (Spearman correlation coefficient, 0.23). CONCLUSIONS: One-time screening was associated with increased AF diagnoses in the top quartile of both predicted screening effect and predicted AF risk. Because predicted effect and risk were only weakly correlated, future AF screening efforts should include both high-effect and high-risk individuals.
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 878-886
Predicting Atrial Fibrillation After Stroke by Combining Polygenic Risk Scores and Clinical Features
BACKGROUND: Because treatment with anticoagulants can prevent recurrent strokes, identification of patients at risk for incident atrial fibrillation (AF) after stroke is crucial. We aimed to investigate whether the addition of AF polygenic risk scores (PRSs) to existing clinical risk predictors could improve prediction of AF after stroke. METHODS: Patients diagnosed with ischemic stroke at the Massachusetts General Hospital between 2003 and 2017 were included. Clinical AF risk was estimated using the Recalibrated Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation model, and genetic risk was estimated using a contemporary AF PRS from 1 093 050 variants. Patients were divided into clinical and genetic risk tertiles. Cox proportional hazards models at different follow-up windows were fit, and C indices and percentile-based net reclassification index were used to determine the improvement of clinical risk models with the addition of AF PRS. RESULTS: Of 1004 stroke survivors, 900 (90%) were non-Hispanic White, 413 (41%) were female, and the mean age was 67 (SD, 14) years. Of 1004 survivors, 239 (23.8%) had prevalent AF and 87 of 765 (11.4%) remaining patients developed incident AF during 5 years of follow-up. AF PRS was associated with greater risk of incident AF after stroke (hazard ratio, 1.21 [95% CI, 0.97–1.50] per 1-SD increase), although the association was not statistically significant. PRS improved discrimination in the first month (area under the curve, 0.78 [95% CI, 0.70–0.82] versus 0.71 [95% CI, 0.60–0.82]; P =0.05), with more modest estimates across longer time windows. CONCLUSIONS: Addition of an AF PRS to clinical risk models may improve identification of individuals at risk of AF after stroke, particularly within the first month.
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 878-886
Predicting Atrial Fibrillation After Stroke by Combining Polygenic Risk Scores and Clinical Features
BACKGROUND: Because treatment with anticoagulants can prevent recurrent strokes, identification of patients at risk for incident atrial fibrillation (AF) after stroke is crucial. We aimed to investigate whether the addition of AF polygenic risk scores (PRSs) to existing clinical risk predictors could improve prediction of AF after stroke. METHODS: Patients diagnosed with ischemic stroke at the Massachusetts General Hospital between 2003 and 2017 were included. Clinical AF risk was estimated using the Recalibrated Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation model, and genetic risk was estimated using a contemporary AF PRS from 1 093 050 variants. Patients were divided into clinical and genetic risk tertiles. Cox proportional hazards models at different follow-up windows were fit, and C indices and percentile-based net reclassification index were used to determine the improvement of clinical risk models with the addition of AF PRS. RESULTS: Of 1004 stroke survivors, 900 (90%) were non-Hispanic White, 413 (41%) were female, and the mean age was 67 (SD, 14) years. Of 1004 survivors, 239 (23.8%) had prevalent AF and 87 of 765 (11.4%) remaining patients developed incident AF during 5 years of follow-up. AF PRS was associated with greater risk of incident AF after stroke (hazard ratio, 1.21 [95% CI, 0.97–1.50] per 1-SD increase), although the association was not statistically significant. PRS improved discrimination in the first month (area under the curve, 0.78 [95% CI, 0.70–0.82] versus 0.71 [95% CI, 0.60–0.82]; P =0.05), with more modest estimates across longer time windows. CONCLUSIONS: Addition of an AF PRS to clinical risk models may improve identification of individuals at risk of AF after stroke, particularly within the first month.
- 18 February 2025
- Published by Elsevier in American Heart Journal
- Vol. 284, 57-66
Impact of a clinical atrial fibrillation risk estimation tool on cardiac rhythm monitor utilization following acute ischemic stroke: A prepost clinical trial
- 18 February 2025
- Published by Elsevier in American Heart Journal
- Vol. 284, 57-66
Impact of a clinical atrial fibrillation risk estimation tool on cardiac rhythm monitor utilization following acute ischemic stroke: A prepost clinical trial
- Open Access
Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial
Background One-time screening trials for atrial fibrillation (AF) have produced mixed results; however, it is unclear if there is a subset of individuals for whom screening would be effective. Identifying such a subgroup would support targeted screening. Methods We conducted a secondary analysis of VITAL-AF, a randomized trial of one-time, single-lead ECG screening during primary care visits. We tested two approaches to identify heterogeneous screening effects. First, we developed an effect-based model for heterogeneous screening effects using a potential outcomes framework. Specifically, we predicted the likelihood of AF diagnosis under both screening and usual care conditions using LASSO, a penalized regression method. The difference between these probabilities was the predicted screening effect. Second, we used the CHARGE-AF score, a validated AF risk model, to test for a heterogeneous screening effect. We used interaction testing to determine if observed AF diagnosis rates in the screening and control groups differed when stratified by decile of the predicted screening effect and predicted AF risk. Results Baseline characteristics were similar between the screening (n=15187) and usual care (n=15078) groups (mean age 74 years, 59% female). On average, screening did not significantly increase the AF diagnosis rate (2.55 vs. 2.30 per 100 person-years, rate difference 0.24, 95%CI −0.18 to 0.67). In the effect-based analysis, in the highest decile of predicted screening efficacy (n=3026), AF diagnosis rates were higher in the screening group (6.5 vs. 3.06 per 100 person-years, rate difference 3.45, 95%CI 1.62 to 5.28, interaction p-value 0.003). In this group, the mean age was 84 years, 68% were female, and 55% had vascular disease. The risk-based analysis did not identify a subgroup where screening was more effective. Predicted screening effectiveness and predicted baseline AF risk were poorly correlated and demonstrated a U-shaped relationship (Spearman coefficient 0.13). Conclusions In a secondary analysis of the VITAL-AF trial, we identified a small subgroup where one-time screening was associated with increased AF diagnoses using an effect-based approach. In this study, predicted AF risk was a poor proxy for predicted screening efficacy. These data caution against the assumption that high AF risk is necessarily correlated with high screening efficacy.
Open AccessIdentifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial
Background One-time screening trials for atrial fibrillation (AF) have produced mixed results; however, it is unclear if there is a subset of individuals for whom screening would be effective. Identifying such a subgroup would support targeted screening. Methods We conducted a secondary analysis of VITAL-AF, a randomized trial of one-time, single-lead ECG screening during primary care visits. We tested two approaches to identify heterogeneous screening effects. First, we developed an effect-based model for heterogeneous screening effects using a potential outcomes framework. Specifically, we predicted the likelihood of AF diagnosis under both screening and usual care conditions using LASSO, a penalized regression method. The difference between these probabilities was the predicted screening effect. Second, we used the CHARGE-AF score, a validated AF risk model, to test for a heterogeneous screening effect. We used interaction testing to determine if observed AF diagnosis rates in the screening and control groups differed when stratified by decile of the predicted screening effect and predicted AF risk. Results Baseline characteristics were similar between the screening (n=15187) and usual care (n=15078) groups (mean age 74 years, 59% female). On average, screening did not significantly increase the AF diagnosis rate (2.55 vs. 2.30 per 100 person-years, rate difference 0.24, 95%CI −0.18 to 0.67). In the effect-based analysis, in the highest decile of predicted screening efficacy (n=3026), AF diagnosis rates were higher in the screening group (6.5 vs. 3.06 per 100 person-years, rate difference 3.45, 95%CI 1.62 to 5.28, interaction p-value 0.003). In this group, the mean age was 84 years, 68% were female, and 55% had vascular disease. The risk-based analysis did not identify a subgroup where screening was more effective. Predicted screening effectiveness and predicted baseline AF risk were poorly correlated and demonstrated a U-shaped relationship (Spearman coefficient 0.13). Conclusions In a secondary analysis of the VITAL-AF trial, we identified a small subgroup where one-time screening was associated with increased AF diagnoses using an effect-based approach. In this study, predicted AF risk was a poor proxy for predicted screening efficacy. These data caution against the assumption that high AF risk is necessarily correlated with high screening efficacy.
- 18 April 2024
- Published by SAGE Publications in International Journal of Stroke
- Vol. 19 (8) , 898-906
Predicting post-stroke cognitive impairment using electronic health record data
Background: Secondary prevention interventions to reduce post-stroke cognitive impairment (PSCI) can be aided by the early identification of high-risk individuals who would benefit from risk factor modification. Aims: To develop and evaluate a predictive model to identify patients at increased risk of PSCI over 5 years using data easily accessible from electronic health records. Methods: Cohort study that included primary care patients from two academic medical centers. Patients were aged 45 years or older, without prior stroke or prevalent cognitive impairment, with primary care visits and an incident ischemic stroke between 2003 and 2016 (development/internal validation cohort) or 2010 and 2022 (external validation cohort). Predictors of PSCI were ascertained from the electronic health record. The outcome was incident dementia/cognitive impairment within 5 years and beginning 3 months following stroke, ascertained using International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) codes. For model variable selection, we considered potential predictors of PSCI and constructed 400 bootstrap samples with two-thirds of the model derivation sample. We ran 10-fold cross-validated Cox proportional hazards models using a least absolute shrinkage and selection operator (LASSO) penalty. Variables selected in >25% of samples were included. Results: The analysis included 332 incident diagnoses of PSCI in the development cohort (n = 3741), and 161 and 128 incident diagnoses in the internal (n = 1925) and external (n = 2237) validation cohorts, respectively. The C-statistic for predicting PSCI was 0.731 (95% confidence interval (CI): 0.694–0.768) in the internal validation cohort, and 0.724 (95% CI: 0.681–0.766) in the external validation cohort. A risk score based on the beta coefficients of predictors from the development cohort stratified patients into low (0–7 points), intermediate (8–11 points), and high (12–23 points) risk groups. The hazard ratios (HRs) for incident PSCI were significantly different by risk categories in internal (high, HR: 6.2, 95% CI: 4.1–9.3; Intermediate, HR: 2.7, 95% CI: 1.8–4.1) and external (high, HR: 6.1, 95% CI: 3.9–9.6; Intermediate, HR: 2.8, 95% CI: 1.9–4.3) validation cohorts. Conclusion: Five-year risk of PSCI can be accurately predicted using routinely collected data. Model output can be used to risk stratify and identify individuals at increased risk for PSCI for preventive efforts. Data access statement: Mass General Brigham data contain protected health information and cannot be shared publicly. The data processing scripts used to perform analyses will be made available to interested researchers upon reasonable request to the corresponding author.
- 18 April 2024
- Published by SAGE Publications in International Journal of Stroke
- Vol. 19 (8) , 898-906
Predicting post-stroke cognitive impairment using electronic health record data
Background: Secondary prevention interventions to reduce post-stroke cognitive impairment (PSCI) can be aided by the early identification of high-risk individuals who would benefit from risk factor modification. Aims: To develop and evaluate a predictive model to identify patients at increased risk of PSCI over 5 years using data easily accessible from electronic health records. Methods: Cohort study that included primary care patients from two academic medical centers. Patients were aged 45 years or older, without prior stroke or prevalent cognitive impairment, with primary care visits and an incident ischemic stroke between 2003 and 2016 (development/internal validation cohort) or 2010 and 2022 (external validation cohort). Predictors of PSCI were ascertained from the electronic health record. The outcome was incident dementia/cognitive impairment within 5 years and beginning 3 months following stroke, ascertained using International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) codes. For model variable selection, we considered potential predictors of PSCI and constructed 400 bootstrap samples with two-thirds of the model derivation sample. We ran 10-fold cross-validated Cox proportional hazards models using a least absolute shrinkage and selection operator (LASSO) penalty. Variables selected in >25% of samples were included. Results: The analysis included 332 incident diagnoses of PSCI in the development cohort (n = 3741), and 161 and 128 incident diagnoses in the internal (n = 1925) and external (n = 2237) validation cohorts, respectively. The C-statistic for predicting PSCI was 0.731 (95% confidence interval (CI): 0.694–0.768) in the internal validation cohort, and 0.724 (95% CI: 0.681–0.766) in the external validation cohort. A risk score based on the beta coefficients of predictors from the development cohort stratified patients into low (0–7 points), intermediate (8–11 points), and high (12–23 points) risk groups. The hazard ratios (HRs) for incident PSCI were significantly different by risk categories in internal (high, HR: 6.2, 95% CI: 4.1–9.3; Intermediate, HR: 2.7, 95% CI: 1.8–4.1) and external (high, HR: 6.1, 95% CI: 3.9–9.6; Intermediate, HR: 2.8, 95% CI: 1.9–4.3) validation cohorts. Conclusion: Five-year risk of PSCI can be accurately predicted using routinely collected data. Model output can be used to risk stratify and identify individuals at increased risk for PSCI for preventive efforts. Data access statement: Mass General Brigham data contain protected health information and cannot be shared publicly. The data processing scripts used to perform analyses will be made available to interested researchers upon reasonable request to the corresponding author.
- Open Access
Predicting post-stroke cognitive impairment using electronic health record data
Importance: Secondary prevention interventions to reduce post-stroke cognitive impairment (PSCI) can be aided by the early identification of high-risk individuals who would benefit from risk factor modification. Objective: To develop and evaluate a predictive model to identify patients at increased risk of PSCI over 5 years using data easily accessible from electronic health records. Design: Cohort study with patients enrolled between 2003-2016 with follow-up through 2022. Setting: Primary care practices affiliated with two academic medical centers. Participants: Individuals 45 years or older, without prior stroke or prevalent cognitive impairment, with primary care visits and an incident ischemic stroke between 2003-2016 (development/internal validation cohort) or 2010-2022 (external validation cohort). Exposures: Predictors of PSCI were ascertained from the electronic health record. Main Outcome: The outcome was incident dementia/cognitive impairment within 5 years and beginning 3 months following stroke, ascertained using ICD-9/10 codes. For model variable selection, we considered potential predictors of PSCI and constructed 400 bootstrap samples with two-thirds of the model derivation sample. We ran 10-fold cross-validated Cox proportional hazards models using a least absolute shrinkage and selection operator (LASSO) penalty. Variables selected in >25% of samples were included. Results: The analysis included 332 incident diagnoses of PSCI in the development cohort (n=3,741), and 161 and 128 incident diagnoses in the internal (n=1,925) and external (n=2,237) validation cohorts. The c-statistic for predicting PSCI was 0.731 (95% CI: 0.694-0.768) in the internal validation cohort, and 0.724 (95% CI: 0.681-0.766) in the external validation cohort. A risk score based on the beta coefficients of predictors from the development cohort stratified patients into low (0-7 points), intermediate (8-11 points), and high (12-35 points) risk groups. The hazard ratios for incident PSCI were significantly different by risk categories in internal (High, HR: 6.2, 95% CI 4.1-9.3; Intermediate, HR 2.7, 95% CI: 1.8-4.1) and external (High, HR: 6.1, 95% CI: 3.9-9.6; Intermediate, HR 2.8, 95% CI: 1.9-4.3) validation cohorts. Conclusions and Relevance: Five-year risk of PSCI can be accurately predicted using routinely collected data. Model output can be used to risk stratify and identify individuals at increased risk for PSCI for preventive efforts.
Open AccessPredicting post-stroke cognitive impairment using electronic health record data
Importance: Secondary prevention interventions to reduce post-stroke cognitive impairment (PSCI) can be aided by the early identification of high-risk individuals who would benefit from risk factor modification. Objective: To develop and evaluate a predictive model to identify patients at increased risk of PSCI over 5 years using data easily accessible from electronic health records. Design: Cohort study with patients enrolled between 2003-2016 with follow-up through 2022. Setting: Primary care practices affiliated with two academic medical centers. Participants: Individuals 45 years or older, without prior stroke or prevalent cognitive impairment, with primary care visits and an incident ischemic stroke between 2003-2016 (development/internal validation cohort) or 2010-2022 (external validation cohort). Exposures: Predictors of PSCI were ascertained from the electronic health record. Main Outcome: The outcome was incident dementia/cognitive impairment within 5 years and beginning 3 months following stroke, ascertained using ICD-9/10 codes. For model variable selection, we considered potential predictors of PSCI and constructed 400 bootstrap samples with two-thirds of the model derivation sample. We ran 10-fold cross-validated Cox proportional hazards models using a least absolute shrinkage and selection operator (LASSO) penalty. Variables selected in >25% of samples were included. Results: The analysis included 332 incident diagnoses of PSCI in the development cohort (n=3,741), and 161 and 128 incident diagnoses in the internal (n=1,925) and external (n=2,237) validation cohorts. The c-statistic for predicting PSCI was 0.731 (95% CI: 0.694-0.768) in the internal validation cohort, and 0.724 (95% CI: 0.681-0.766) in the external validation cohort. A risk score based on the beta coefficients of predictors from the development cohort stratified patients into low (0-7 points), intermediate (8-11 points), and high (12-35 points) risk groups. The hazard ratios for incident PSCI were significantly different by risk categories in internal (High, HR: 6.2, 95% CI 4.1-9.3; Intermediate, HR 2.7, 95% CI: 1.8-4.1) and external (High, HR: 6.1, 95% CI: 3.9-9.6; Intermediate, HR 2.8, 95% CI: 1.9-4.3) validation cohorts. Conclusions and Relevance: Five-year risk of PSCI can be accurately predicted using routinely collected data. Model output can be used to risk stratify and identify individuals at increased risk for PSCI for preventive efforts.
- Open Access
- 2 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (1) , e032126
Characteristics and Attitudes of Wearable Device Users and Nonusers in a Large Health Care System
Background: Consumer wearable devices with health and wellness features are increasingly common and may enhance disease detection and management. Yet studies informing relationships between wearable device use, attitudes toward device data, and comprehensive clinical profiles are lacking. Methods and Results: WATCH‐IT (Wearable Activity Tracking for Comprehensive Healthcare‐Integrated Technology) studied adults receiving longitudinal primary or ambulatory cardiovascular care in the Mass General Brigham health care system from January 2010 to July 2021. Participants completed a 20‐question electronic survey about perceptions and use of consumer wearable devices, with responses linked to electronic health records. Multivariable logistic regression was used to identify factors associated with device use. Among 214 992 individuals receiving longitudinal primary or cardiovascular care with an active electronic portal, 11 121 responded (5.2%). Most respondents (55.8%) currently used a wearable device, and most nonusers (95.3%) would use a wearable if provided at no cost. Although most users (70.2%) had not shared device data with their doctor previously, most believed it would be very (20.4%) or moderately (34.4%) important to share device‐related health information with providers. In multivariable models, older age (odds ratio [OR], 0.80 per 10‐year increase [95% CI, 0.77–0.82]), male sex (OR, 0.87 [95% CI, 0.80–0.95]), and heart failure (OR, 0.75 [95% CI, 0.63–0.89]) were associated with lower odds of wearable device use, whereas higher median income (OR, 1.08 per 1‐quartile increase [95% CI, 1.04–1.12]) and care in a cardiovascular medicine clinic (OR, 1.17 [95% CI, 1.05–1.30]) were associated with greater odds of device use. Conclusions: Among patients in primary and cardiovascular medicine clinics, consumer wearable device use is common, and most users perceive value in wearable health data.
- 2 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (1) , e032126
Open AccessCharacteristics and Attitudes of Wearable Device Users and Nonusers in a Large Health Care System
Background: Consumer wearable devices with health and wellness features are increasingly common and may enhance disease detection and management. Yet studies informing relationships between wearable device use, attitudes toward device data, and comprehensive clinical profiles are lacking. Methods and Results: WATCH‐IT (Wearable Activity Tracking for Comprehensive Healthcare‐Integrated Technology) studied adults receiving longitudinal primary or ambulatory cardiovascular care in the Mass General Brigham health care system from January 2010 to July 2021. Participants completed a 20‐question electronic survey about perceptions and use of consumer wearable devices, with responses linked to electronic health records. Multivariable logistic regression was used to identify factors associated with device use. Among 214 992 individuals receiving longitudinal primary or cardiovascular care with an active electronic portal, 11 121 responded (5.2%). Most respondents (55.8%) currently used a wearable device, and most nonusers (95.3%) would use a wearable if provided at no cost. Although most users (70.2%) had not shared device data with their doctor previously, most believed it would be very (20.4%) or moderately (34.4%) important to share device‐related health information with providers. In multivariable models, older age (odds ratio [OR], 0.80 per 10‐year increase [95% CI, 0.77–0.82]), male sex (OR, 0.87 [95% CI, 0.80–0.95]), and heart failure (OR, 0.75 [95% CI, 0.63–0.89]) were associated with lower odds of wearable device use, whereas higher median income (OR, 1.08 per 1‐quartile increase [95% CI, 1.04–1.12]) and care in a cardiovascular medicine clinic (OR, 1.17 [95% CI, 1.05–1.30]) were associated with greater odds of device use. Conclusions: Among patients in primary and cardiovascular medicine clinics, consumer wearable device use is common, and most users perceive value in wearable health data.
- Open Access
- 19 December 2023
- Published by Wolters Kluwer Health in Journal of Cardiopulmonary Rehabilitation and Prevention
- Vol. 44 (2) , 143-145
A Lifestyle Modification Program for Secondary Prevention of Atrial Fibrillation: Introductory Findings
- 19 December 2023
- Published by Wolters Kluwer Health in Journal of Cardiopulmonary Rehabilitation and Prevention
- Vol. 44 (2) , 143-145
Open AccessA Lifestyle Modification Program for Secondary Prevention of Atrial Fibrillation: Introductory Findings
- Open Access
- 26 September 2023
- Published by Springer Nature in Research Square
A Lifestyle Modification Program for Secondary Prevention of Atrial Fibrillation: A Pilot Study
Background Lifestyle modification programs, such as cardiac rehabilitation, may reduce atrial fibrillation (AF) burden and improve quality of life (QOL), but remain unproven. The objective of this pilot study was to assess feasibility, acceptability, and preliminary effectiveness of an exercise and nutrition-based cardiac rehabilitation-like program for AF patients. Methods We enrolled overweight adults aged ≥ 30 years with symptomatic AF in a 12-week cardiac lifestyle group program, including 6 virtual and 6 in-person visits. All visits included discussion and education about nutrition, exercise, and behavior modification. In-person visits included supervised aerobic exercise and strength training. Outcomes at baseline and 12 weeks included feasibility of participation, acceptability, change in weight and BMI, and changes in survey-based AF burden, symptoms, and QOL. Results From 84 invitees, 11 (13.1%) were enrolled (mean age 64; baseline BMI 38 kg/m2); 9 (82%) completed the program. Patients attended an average of 9.7 (81%) visits (Range: 6–11). Mean weight loss was 9.1 pounds (Range: 0–16); mean BMI decrease was 1.4 kg/m2 (Range: 0-2.6). Patients found the program helpful overall: all reported making diet and exercise changes during the program. Compared to baseline, patients reported decreased AF burden (12.9 vs. 11.7, p = 0.03) and symptom (10.1 vs. 5.6, p = 0.003) scores at the conclusion of the program. Patients also reported increased QOL overall (68.9 vs. 86.4, p = 0.001) Conclusions Participation in a cardiac rehab-like program was feasible and acceptable for overweight patients with symptomatic AF. Results suggest preliminary effectiveness of the program for reducing AF burden and symptoms and increasing QOL.
- 26 September 2023
- Published by Springer Nature in Research Square
Open AccessA Lifestyle Modification Program for Secondary Prevention of Atrial Fibrillation: A Pilot Study
Background Lifestyle modification programs, such as cardiac rehabilitation, may reduce atrial fibrillation (AF) burden and improve quality of life (QOL), but remain unproven. The objective of this pilot study was to assess feasibility, acceptability, and preliminary effectiveness of an exercise and nutrition-based cardiac rehabilitation-like program for AF patients. Methods We enrolled overweight adults aged ≥ 30 years with symptomatic AF in a 12-week cardiac lifestyle group program, including 6 virtual and 6 in-person visits. All visits included discussion and education about nutrition, exercise, and behavior modification. In-person visits included supervised aerobic exercise and strength training. Outcomes at baseline and 12 weeks included feasibility of participation, acceptability, change in weight and BMI, and changes in survey-based AF burden, symptoms, and QOL. Results From 84 invitees, 11 (13.1%) were enrolled (mean age 64; baseline BMI 38 kg/m2); 9 (82%) completed the program. Patients attended an average of 9.7 (81%) visits (Range: 6–11). Mean weight loss was 9.1 pounds (Range: 0–16); mean BMI decrease was 1.4 kg/m2 (Range: 0-2.6). Patients found the program helpful overall: all reported making diet and exercise changes during the program. Compared to baseline, patients reported decreased AF burden (12.9 vs. 11.7, p = 0.03) and symptom (10.1 vs. 5.6, p = 0.003) scores at the conclusion of the program. Patients also reported increased QOL overall (68.9 vs. 86.4, p = 0.001) Conclusions Participation in a cardiac rehab-like program was feasible and acceptable for overweight patients with symptomatic AF. Results suggest preliminary effectiveness of the program for reducing AF burden and symptoms and increasing QOL.